FibroGen (NASDAQ:FGEN) CEO Thomas B. Neff sold 39,636 shares of the company’s stock in a transaction dated Thursday, April 5th. The shares were sold at an average price of $45.59, for a total value of $1,807,005.24. Following the completion of the transaction, the chief executive officer now owns 2,950,813 shares in the company, valued at approximately $134,527,564.67. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Shares of NASDAQ FGEN opened at $44.90 on Monday. The company has a market capitalization of $3,711.75, a P/E ratio of -25.95 and a beta of 1.89. FibroGen has a 52 week low of $24.25 and a 52 week high of $63.00. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.70 and a quick ratio of 9.70.
FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.01. The business had revenue of $42.51 million during the quarter, compared to analysts’ expectations of $45.37 million. FibroGen had a negative return on equity of 32.08% and a negative net margin of 100.43%. equities analysts forecast that FibroGen will post -1.35 earnings per share for the current year.
A number of brokerages have recently weighed in on FGEN. ValuEngine upgraded FibroGen from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Leerink Swann reiterated an “outperform” rating and issued a $88.00 target price (up previously from $80.00) on shares of FibroGen in a report on Wednesday, February 28th. Mizuho reiterated a “hold” rating and issued a $61.00 target price on shares of FibroGen in a report on Thursday, March 29th. Zacks Investment Research downgraded FibroGen from a “hold” rating to a “sell” rating in a report on Monday, March 5th. Finally, TheStreet upgraded FibroGen from a “d” rating to a “c-” rating in a report on Tuesday, February 27th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $66.67.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. grew its stake in shares of FibroGen by 4.0% in the 4th quarter. BlackRock Inc. now owns 6,326,075 shares of the biopharmaceutical company’s stock valued at $299,855,000 after buying an additional 244,617 shares in the last quarter. Farallon Capital Management LLC grew its stake in shares of FibroGen by 50.7% in the 4th quarter. Farallon Capital Management LLC now owns 1,657,500 shares of the biopharmaceutical company’s stock valued at $78,566,000 after buying an additional 557,500 shares in the last quarter. First Trust Advisors LP grew its stake in shares of FibroGen by 1,058.4% in the 4th quarter. First Trust Advisors LP now owns 776,640 shares of the biopharmaceutical company’s stock valued at $36,813,000 after buying an additional 709,598 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of FibroGen by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 723,869 shares of the biopharmaceutical company’s stock valued at $34,310,000 after buying an additional 2,312 shares in the last quarter. Finally, Carillon Tower Advisers Inc. bought a new stake in shares of FibroGen in the 4th quarter valued at approximately $282,486,000. 61.39% of the stock is owned by institutional investors and hedge funds.
WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/09/fibrogen-fgen-ceo-sells-1807005-24-in-stock.html.
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.